adg126,tpst-1120,bevacizumab,tocilizumab,atezolizumab,ro7247669,tiragolumab
adagene,roche,jw pharma,tempest
['atezo', 'hcc', 'tiragolumab', 'morpheus-liver']
 asco hcc are we entering the triplet era for hcc?
-phase ib/ii morpheus-liver: addition of tiragolumab (anti-tigit) to atezobev significantly improved orr (42.5% vs a disappointing 11.1%) &amp; pfs
-no significant ae increase
-phase iii starting soon
#asco23 
Medical Oncologist and PhD student at Imperial College London.
HCC, immuno-oncology.
Curiosity-driven.